Opinion|Videos|June 19, 2024
Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
- Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
4
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
5